Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2025 Jun;28(6):e70310.
doi: 10.1111/1756-185X.70310.

Evidence- and Consensus-Based Recommendations for the Screening, Diagnosis, and Management of Secondary Hypogammaglobulinemia in Patients With Systemic Autoimmune Rheumatic Diseases by the Taiwan College of Rheumatology Experts

Affiliations
Review

Evidence- and Consensus-Based Recommendations for the Screening, Diagnosis, and Management of Secondary Hypogammaglobulinemia in Patients With Systemic Autoimmune Rheumatic Diseases by the Taiwan College of Rheumatology Experts

Yen-Po Tsao et al. Int J Rheum Dis. 2025 Jun.

Abstract

Secondary hypogammaglobulinemia (SHG) is characterized by reduced serum immunoglobulin (Ig) levels and is typically caused by immunosuppressive therapy or certain diseases. Patients with systemic autoimmune rheumatic diseases (SARDs) and hematological malignancies are particularly susceptible to developing SHG due to underlying diseases and the use of immunosuppressive medications, such as B-cell-targeted agents. Consequently, SHG significantly contributes to increased risks of severe infections and mortality in SARDs patients. Considering the lack of a unified strategy for managing SHG, the Taiwan College of Rheumatology (TCR) aimed to formulate consensus recommendations for the screening, diagnosis, and management of SHG. These recommendations were developed based on emerging evidence during a face-to-face meeting of the TCR committee (nine immunologists and rheumatologists), and utilizing the modified Delphi process. This meeting involved a comprehensive review of the current evidence, using the Grading of Recommendations, Assessment, Development, and Evaluation (GRADE) methodology. Thirteen consensus recommendations were developed to emphasize the importance of early detection and optimal treatment of SHG. Furthermore, effective prevention of infections through risk assessment alongside timely and regular monitoring of IgG levels was highlighted. The recommendations also included anti-infective therapies and intravenous Ig replacement, offering valuable guidance to rheumatologists in managing SHG. This consensus will be regularly updated as newer evidence emerges.

Keywords: B‐cell‐targeted therapy; consensus recommendations; immunoglobulin replacement therapy; immunosuppression; infection; secondary hypogammaglobulinemia; systemic autoimmune rheumatic diseases.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflicts of interest.

Figures

FIGURE 1
FIGURE 1
TCR consensus statement formulation process. *Composed of nine rheumatologists and immunologists. GRADE, grading of recommendations, assessment, development and evaluation; TCR, Taiwan College of Rheumatology.
FIGURE 2
FIGURE 2
The screening, monitoring, management, and follow‐up algorithm of SHG in SARD patients. ABW, adjusted body weight; BCTT, B‐cell‐targeted therapy; IBW, ideal body weight; Ig, immunoglobulin; IgRT, immunoglobulin replacement therapy; IVIg, intravenous immunoglobulin; LLN, lower limit of normal; R, recommendation; SARDs, systemic autoimmune rheumatic diseases; SHG, secondary hypogammaglobulinemia.

Similar articles

References

    1. Otani I. M., Lehman H. K., Jongco A. M., et al., “Practical Guidance for the Diagnosis and Management of Secondary Hypogammaglobulinemia: A Work Group Report of the AAAAI Primary Immunodeficiency and Altered Immune Response Committees,” Journal of Allergy and Clinical Immunology 149, no. 5 (2022): 1525–1560, 10.1016/j.jaci.2022.01.025. - DOI - PubMed
    1. Duraisingham S. S., Buckland M., Dempster J., Lorenzo L., Grigoriadou S., and Longhurst H. J., “Primary vs. Secondary Antibody Deficiency: Clinical Features and Infection Outcomes of Immunoglobulin Replacement,” PLoS One 9, no. 6 (2014): e100324, 10.1371/journal.pone.0100324. - DOI - PMC - PubMed
    1. Akatsuka M., Masuda Y., Tatsumi H., and Sonoda T., “Efficacy of Intravenous Immunoglobulin Therapy for Patients With Sepsis and Low Immunoglobulin G Levels: A Single‐Center Retrospective Study,” Clinical Therapeutics 44, no. 2 (2022): 295–303, 10.1016/j.clinthera.2021.12.008. - DOI - PubMed
    1. Patel S. Y., Carbone J., and Jolles S., “The Expanding Field of Secondary Antibody Deficiency: Causes, Diagnosis, and Management,” Frontiers in Immunology 10 (2019): 33, 10.3389/fimmu.2019.00033. - DOI - PMC - PubMed
    1. Chinen J. and Shearer W. T., “Secondary Immunodeficiencies, Including HIV Infection,” Journal of Allergy and Clinical Immunology 125, no. 2 Suppl 2 (2010): S195–S203, 10.1016/j.jaci.2009.08.040. - DOI - PMC - PubMed

MeSH terms